During the last session, Taysha Gene Therapies Inc (NASDAQ:TSHA)’s traded shares were 1.42 million, with the beta value of the company hitting 0.35. At the end of the trading day, the stock’s price was $2.30, reflecting an intraday loss of -2.13% or -$0.05. The 52-week high for the TSHA share is $3.89, that puts it down -69.13 from that peak though still a striking 78.26% gain since the share price plummeted to a 52-week low of $0.50. The company’s market capitalization is $430.15M, and the average trade volume was 2.76 million shares over the past three months.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Taysha Gene Therapies Inc (TSHA) registered a -2.13% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.13% in intraday trading to $2.30, hitting a weekly high. The stock’s 5-day price performance is -4.56%, and it has moved by -24.84% in 30 days. Based on these gigs, the overall price performance for the year is 260.78%.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Statistics show that Taysha Gene Therapies Inc has outperformed its competitors in share price, compared to the industry in which it operates. Taysha Gene Therapies Inc (TSHA) shares have gone up 2.22% during the last six months, with a year-to-date growth rate more than the industry average at 59.38% against 21.80. In the rating firms’ projections, revenue will decrease -33.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.56M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 2.57M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 4.71M and 2.4M respectively. In this case, analysts expect current quarter sales to shrink by -45.60% and then jump by 7.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -137.69%. While earnings are projected to return 57.71% in 2024.
TSHA Dividends
Taysha Gene Therapies Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
